Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus Sep 7, 2023 12:00PM
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Aug 21, 2023 09:15AM
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering Aug 4, 2023 01:43PM
Adamis Pharmaceuticals (ADMP) Prices 5.93M Share Offering at $1.35/sh Aug 2, 2023 08:30AM
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering Aug 2, 2023 08:30AM
View Older Stories

Jul 28, 2023 08:30AM Adamis Pharmaceuticals (ADMP) to Fund ZIMHI Study with University of Leiden Opioid Expert
Jul 28, 2023 08:30AM Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
Jun 26, 2023 07:30AM Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
Jun 22, 2023 07:30AM Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
May 25, 2023 04:26PM Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
May 19, 2023 12:04PM Adamis Pharmaceuticals (ADMP) Announces 1:70 Reverse Stock Split
May 19, 2023 12:00PM Adamis Pharmaceuticals Announces Reverse Stock Split
May 15, 2023 04:47PM Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 04:05PM Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
Mar 16, 2023 04:24PM Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 14, 2023 04:01PM Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
Mar 14, 2023 08:30AM Adamis Pharmaceuticals (ADMP) Announces $3M Share Offering
Mar 14, 2023 08:30AM Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
Feb 27, 2023 04:06PM Adamis Pharmaceuticals (ADMP) will acquire DMK
Feb 27, 2023 04:05PM Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger
Feb 22, 2023 04:02PM Adamis Pharmaceuticals (ADMP) Announce Nasdaq Grants Request for Extension to Comply with Continued Listing Requirements
Feb 22, 2023 04:01PM Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements
Nov 14, 2022 04:10PM Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 7, 2022 04:05PM Adamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate Update
Oct 3, 2022 04:30PM Adamis Pharmaceuticals (ADMP) Announces Review of Strategic Alternatives
Oct 3, 2022 04:30PM Adamis Announces Review of Strategic Alternatives
Sep 21, 2022 07:30AM Adamis Pharmaceuticals (ADMP) Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects Did Not Achieve its Primary Endpoint
Sep 21, 2022 07:30AM Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
Sep 12, 2022 04:09PM Adamis Pharmaceuticals (ADMP) Provides an Enrollment Update on the Phase 2/3 Study of Tempol
Sep 12, 2022 04:05PM Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
Aug 12, 2022 05:00PM Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
Aug 10, 2022 04:02PM Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 8, 2022 07:30AM Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
Jul 29, 2022 08:00AM Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
Jul 29, 2022 07:31AM Adamis Pharmaceuticals (ADMP) Provides Update on Clinical Study Assessing Tempol for Treatment of COVID-19
Jul 29, 2022 07:30AM Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Jul 21, 2022 07:31AM Adamis Pharmaceuticals (ADMP) Issues Letter to Stockholders
Jul 21, 2022 07:30AM Adamis Pharmaceuticals Issues Letter to Stockholders
Jun 1, 2022 08:10AM Adamis Pharmaceuticals (ADMP) Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Jun 1, 2022 08:00AM Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
May 26, 2022 04:07PM Adamis Pharmaceuticals (ADMP) Appoints Vickie Reed to its Board
May 26, 2022 04:05PM Adamis Appoints Vickie Reed to Board of Directors
May 18, 2022 05:00PM Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
May 16, 2022 04:36PM Adamis Pharmaceuticals (ADMP) Reports Q1 Revenue of $1.2M, Net Loss of $155K
May 16, 2022 04:35PM Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 9, 2022 05:56PM Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
Mar 31, 2022 04:49PM Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
Mar 31, 2022 04:14PM US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
Mar 31, 2022 04:14PM US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
Mar 24, 2022 07:30AM Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
Mar 22, 2022 07:33AM Adamis Pharmaceuticals (ADMP) Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
Mar 22, 2022 07:30AM Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
Mar 14, 2022 08:18AM Adamis Pharmaceuticals (ADMP) Announces DSMB Recommends Continuation of Tempol Study for the Treatment of COVID-19
Mar 14, 2022 08:17AM Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Mar 4, 2022 07:31AM Adamis Pharmaceuticals (ADMP) Announces Retirement of Richard C. Williams, Chairman of the Board
View Older Stories